 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareMetabolic Complications: Research
See also: Metabolic Complications Overview
General Lipodystrophy Research
- Surprising Changes in Body Fat With Darunavir Monotherapy (March/April 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange - ACTG 5202 Substudy Finds Little Lipoatrophy but Signs of Bone Loss Across the Board; Devil Is in the Details (February 19, 2010)
A discussion with Grace McComsey, M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Can Carnitine Reduce Diabetes Risk and Improve Body Shape? (September 28, 2009)
From Canadian AIDS Treatment Information Exchange - Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? (April 2009)
Christos Mantzoros, M.D., an associate professor at Harvard Medical School, offers his take on whether there's a future for leptin replacement as a treatment for metabolic complications in HIV-infected patients. (Editorial originally published in the Journal of Clinical Endocrinology & Metabolism.)
From National AIDS Treatment Advocacy Project - Leptin Injections May Help HIVers With Lipoatrophy, Other Metabolic Problems, According to Small Study (April 2009)
The full text of a study published in the Journal of Clinical Endocrinology & Metabolism.
From National AIDS Treatment Advocacy Project - HIV/HCV-Coinfected Patients Appear More Likely Than HIV-Monoinfected Patients to Develop Insulin Resistance After Initiating HAART (February 5, 2008)
From The Body PRO - Body Fat Changes Becoming Less Common as HIVers Use Fat-Friendlier Meds, Study Finds (January 23, 2008)
In HIV Medicine - Study May Disprove Link Between HIV/Hep C Coinfection and Some Metabolic Problems (May 21, 2007)
A pair of new U.S. studies appears to contradict long-held concerns that HIV/hepatitis C-coinfected people have a higher risk of diabetes and lipoatrophy (fat loss).
From aidsmap.com
- Literature Citations for the Management of Metabolic Disorders in HIV-Positive Patients (Regularly Updated)
From U.S. National Institutes of Health - Literature Citations for the Treatment of Lipodystrophy/Lipoatrophy in HIV-Positive Patients (Regularly Updated)
From U.S. National Institutes of Health - Literature Citations for the Diagnosis of Lipodystrophy/Lipoatrophy in HIV-Positive Patients (Regularly Updated)
From U.S. National Institutes of Health - Increased Fat Consumption Observed in People With HIV With High Cholesterol (August 22, 2007)
From aidsmap.com - NRTIs Exposure Increases Diabetes Risk in HIV-Infected Women Over Time (August 20, 2007)
In AIDS - Switch Studies (SWEET and BICOMBO) Explore Metabolic Issues (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Dietary Intervention When Starting HAART Prevents the Increase in Lipids Independently of Drug Regimen: A Randomized Trial (July 25, 2007)
From International AIDS Society - The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Testosterone Levels, Fat Free Mass, Increases Differ According to HIV Drugs Taken (June 4, 2007)
From aidsmap.com - Chewing the Fat Contributes to Dyslipidemia in HIV-Infected Individuals, Study Finds (March 9, 2007)
In aidsmap.com - Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Metabolic Syndrome as Common in HIV-Negative as in HIV-Positive Individuals (February 15, 2007)
From aidsmap.com - My Big Fat Metabolic Study: ACTG A5005s (February 2007)
DEXA outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz or both plus dual nucleosides: long-term results from A5005s, a substudy of ACTG 384.
In HIV JournalView, from The Body PRO
- Lipid Abnormalities in HIV/Hepatitis C Virus-Coinfected Patients (November 2006)
In HIV Medicine - Metabolic Complications of HIV Therapy (September 2006)
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Metabolic Complications at the XVI International AIDS Conference: Part 2 -- Lipids (August 17, 2006)
In XVI International AIDS Conference - Initiation of HAART May Increase Free Testosterone Levels and Fat-Free Mass (August 17, 2006)
In XVI International AIDS Conference - Metabolic Complications at the XVI International AIDS Conference: Part 1 -- An Overview of New Data (August 17, 2006)
In XVI International AIDS Conference - Body Fat Changes in People With HIV (August 14, 2006)
An interview with Todd Brown, M.D., Johns Hopkins School of Medicine.
In The XVI International AIDS Conference - Interventions for Fat Changes: New Research on Glitazones, Metformin and Testosterone (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - PI-Based Therapy Does Not Increase Glucose Intolerance, Gestational Diabetes in Pregnant, HIV-Infected Women (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - HIV JournalView: Metabolic Complications and HAART: Some New Answers and Many More Questions (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Benefit of Rosiglitazone or Metformin for Lipodystrophy Still Unclear (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says (November 3, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com - HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO - HIV JournalView: Exporting Lipodystrophy: d4T Usage in Developing World (July/August 2005)
From The Body PRO - Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Five Ways to Tackle Toxicity (or the Ant, the Spider, and the Bee): 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (January 2005)
[Archived Article]
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Metabolic Syndrome Among HIV-Infected Patients: Prevalence, Characteristics, and Related Factors (January 2005)
Abstract of a study published in Diabetes Care.
From International Association of Physicians in AIDS Care
- HIV JournalView: Exogenous Growth Hormone, an Expensive (and Questionable) Fat Accumulation Treatment (September 2004)
[Archived Article]
From The Body PRO - HIV JournalView: Using Suction-Assisted Lipectomy to Treat Buffalo Hump (September 2004)
[Archived Article]
From The Body PRO - Metabolic Complications of HIV and Its Therapies (July 16, 2004)
[Archived Article]
A detailed overview of recent research.
In The XV International AIDS Conference - A HAART Regimen With Lower Metabolic Effect: Nevirapine Plus Non-Thymidine Analog NRTIs (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO - Kidney Fat Could Be a Predictor of Lipodystrophy (July 6, 2004)
[Archived Article]
Researchers use ultrasound to gauge the likelihood a patient will develop lipodystrophy after starting HAART, or whether a treatment switch will improve existing lipodystrophy.
From aidsmap.com - Vitamins and Exercise May Help HIV-Related Metabolic Disorders (June 19, 2004)
[Archived Article]
In The Advocate - Vitamins, Exercise May Help Metabolic Disorders (June 16, 2004)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Lipid-Lowering Drug Helps Triglyceride Levels in HIVers With Lipodystrophy (June 2004)
[Archived Article]
A daily dose of fenofibrate is found to lower abnormally high triglyceride levels in HIV-positive people with lipodystrophy, without causing any severe side effects.
In American Journal of Medical Science - Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Canadian Company Reports Promising Lipodystrophy Treatment (April 19, 2004)
[Archived Article]
ThGRF has been found to reduce abdominal fat in HIV-infected patients without adversely affecting blood-glucose levels.
From aidsmap.com - Can Atazanavir Reverse Body Fat Changes? (April 8, 2004)
[Archived Article]
Anecdotal evidence recently reported in the journal AIDS suggests that atazanavir (Reyataz) may treat lipodystrophy.
From aidsmap.com - Diabetes Drug and Exercise Help Reduce Heart Disease Risk and Improve Body Shape in HAART Patients (March 12, 2004)
[Archived Article]
From aidsmap.com - CROI 2004 Recap: Metabolic Complications (March 2004)
[Archived Article]
David Wohl, M.D., reviews research highlights from the 11th Conference on Retroviruses and Opportunistic Infections.
In HEPP Report, from Brown Medical School - An Overview of the Metabolic Complications of HIV/HAART (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - CROI 2004 Select Poster Abstracts: Metabolic Complications (January 2004)
From International Association of Physicians in AIDS Care
- Fiber-, Protein-, Calorie-Rich Diet Appears to Protect Against Central Fat Gain in Men (December 11, 2003)
[Archived Article]
From aidsmap.com - High-Fiber Diet in HIV-Positive Men Is Associated With Lower Risk of Developing Fat Deposition (November 2003)
[Archived Article]
Abstract of a study in the American Journal of Clinical Nutrition.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - New Form of Liposuction Able to Reduce Buffalo Hump -- At Least in the Short Term (October 20, 2003)
[Archived Article]
A combination of liposuction and ultrasound is found to make buffalo humps smaller, but for half of the study patients the hump eventually grew back fully.
From aidsmap.com - Sublime Versus Simple Side Effect Stories (or, Forget the Adiponectin, Just Stop Smoking) -- 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (October 2003)
[Archived Article]
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Dyslipidemia: Change to Tenofovir? (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Women Get More Lipodystrophy Than Men, Says Italian Study (September 10, 2003)
[Archived Article]
In this large study, women on HAART were found to be at a greater risk for developing body fat changes than men -- although men generally seemed to LOSE fat more often than women.
From aidsmap.com - FRAM Study: The Skinny on Lipodystrophy (September 2003)
[Archived Article]
2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Antioxidants Have Little Benefit in People With Lipoatrophy (August 29, 2003)
[Archived Article]
A combination of vitamin E, vitamin C and N-acetylcysteine has positive and negative health results.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Little Lipodystrophy Seen With Either Atazanavir or Efavirenz (July 16, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - FRAM Study Finds a Lack of Association Between Lipoatrophy and Central Fat Gain (July 15, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - HIV-Positive Teenagers With Lipodystrophy Have Lower Growth Hormone Secretion (July 1, 2003)
[Archived Article]
Researchers conducting a small study believe they've found the first link between lipodystrophy and lack of growth hormone in children on HAART.
From aidsmap.com - New Drug Being Studied for Lipodystrophy (June 23, 2003)
[Archived Article]
The promise of TH9507, a peptide that stimulates growth hormone production.
From Canadian AIDS Treatment Information Exchange - Increased Lipodystrophy Is Associated With Increased Exposure to Highly Active Antiretroviral Therapy in HIV-Infected Children (June 2003)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care - FRAM Frameshift? (May 2003)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Diabetes Risk Triples in Women on PIs (April 24, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Increased Lipodystrophy Is Associated With Increased Exposure to Highly Active Antiretroviral Therapy in HIV-Infected Children (April 15, 2003)
[Archived Article]
In Journal of AIDS - Emory Researchers Identify Link Between Lipid Abnormalities and AIDS Therapy (April 4, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Bezafibrate Improves Glucose Uptake and Endothelial Function in HIV Patient (March 28, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Metabolic and Morphologic Complications in HIV Disease: What's New (March 11, 2003)
[Archived Article]
A review of recent findings on insulin resistance, body fat changes and related problems.
In The PRN Notebook - Retrovirus 2003: Management of Metabolic Complications (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Nutrition and Exercise to Manage Lipodystrophy (January 2003)
[Archived Article]
Research from the 2002 International AIDS Conference.
In Project Inform Perspective, from Project Inform - Report From the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (January 2003)
[Archived Article]
In Hopkins HIV Report - Segmental BIA: Can We Measure Lipodystrophy? (December 2002/January 2003)
[Archived Article]
Emerging data reported at the ninth annual ANSA Conference.
In Survival News, from AIDS Survival Project
- Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Cost-Effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults (November 25, 2002)
[Archived Article]
A study asserts that, generally speaking, the risks of lipodystrophy and heart disease are outweighed by the benefits of early HIV treatment.
In Archives of Internal Medicine - National Institutes of Health Awards $1.95 Million to Study New Treatments for Drug Side Effects (November 22, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Study Reports Self-Image Concerns in HIV-Positive People With Lipodystrophy (October 22, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - HIV Positive May Risk Death to Avoid Side Effect of Meds (October 2, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - The Case Against Zerit (October 2002)
[Archived Article]
Research increasingly points to NRTIs -- particularly d4T -- as a likely culprit in metabolic disorders.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Overview of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Twelve Weeks of Atazanavir Treatment Reverses Nelfinavir-Associated Hyperlipidemia: Results From BMS AI424-044 (September 24, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - The Viramune Hepatic Safety Project: Analysis of Symptomatic Hepatic Events (September 24, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - The Mechanisms of Lipodystrophy: Leptin, Lipodystrophy and Insulin Resistance; Treatment of Non-HIV Lipodystrophy With Thiazolidinediones and Leptin (September 23, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Cancer Drug for Male Breast Enlargement? (September 18, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange - Lactic Acidosis: Watching and Waiting (September 2002)
[Archived Article]
Metformin (glucophage), used to treat diabetes, may add to the lactic acidosis risk posed by some antiretrovirals.
In HIV Treatment ALERTS!, from The Center for AIDS - Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir, Efavirenz or Nevirapine; Twelve-Month Results of a Randomized Study (LIPNEFA) (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Fat Redistribution and Metabolic Changes With a Nucleoside-Reverse Transcriptase Inhibitor, Non-NRTI, or Protease Inhibitor-Based Regimen: FRAMS Substudy of the Atlantic Study (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Disturbing Metabolic Disturbances: Clinical Impact (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Disturbing Metabolic Disturbances: Basic Science (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Quantification of Mitochondrial DNA in Human Cells Using Real-Time PCR With Fluorogenic Reporters (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Special Retrovirus Update: Lipodystrophy (March 28, 2002)
[Archived Article]
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project - Lipoatrophy and Antiretroviral Drug Changes (March 8, 2002)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News - 9th Retrovirus Conference Coverage: Lipodystrophy: To Switch or Not to Switch? (Spring 2002)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project - 9th Retrovirus Conference Coverage: Lipodystrophy Treatment (Spring 2002)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project - 9th Retrovirus Conference Coverage: Lipodystrophy Definition (Spring 2002)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project - Lipodystrophy Update (March 2002)
[Archived Article]
To read PDF, click here.
In Project Inform Perspective, from Project Inform - A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Lipodystrophy Treatment After Barcelona Conference: Interview With Howard Grossman, M.D.
From AIDS Treatment News
- Metabolic Complications of HIV Disease (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Triglyceride Increase Can Predict Lipodystrophy in HIV Patients Under HAART (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Associations Between Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and HIV-Associated Lipodystrophy Syndrome (HALS) in the Dagna-LipART Cohort Study (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Rise in HDL Cholesterol Associated With Nevirapine Containing Antiretroviral Therapy in HIV-1 Infected Patients Is Sustained Over 48 Weeks of Treatment (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Switching From PI-Based to NNRTI-Based Regimens: Clinical and Metabolic Outcomes (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - The Impact of First Line Therapies on Lipid Metabolism: The FRAMS Data (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - HIV-Positive Individuals and Fat Redistribution: Diet Modification May Be the Key (October 1, 2001)
[Archived Article]
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project - Growth Hormone Used to Treat Humps and Excess Fat (August 21, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange - Carnitine for High Triglycerides (July 31, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange - Risk of Lipodystrophy in HIV-1-Infected Patients Treated with Protease Inhibitors: A Prospective Cohort Study (July 2001)
[Archived Article]
In Body Positive, from Body Positive - Insulin Resistance in HIV Lipodystrophy Syndrome (July 2001)
[Archived Article]
In Body Positive, from Body Positive - The Phenomena Formerly Known as Lipodystrophy (March 22, 2001)
[Archived Article]
Report from the 8th Conference on Retroviruses and Opportunistic Infections.
In STEP Ezine, from Seattle Treatment Education Project - Lipodystrophy Update: The Continuing Saga (March 2001)
[Archived Article]
To read PDF, click here.
In Project Inform Perspective, from Project Inform - ACTG 5056: Metabolic Status and Cardiovascular Disease Risk for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir-Containing Regimen (ACTG 372A) (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Metabolic Complications of HIV-1 Disease (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - An Open Randomized Study on the Replacement of HIV-1 Protease Inhibitors by Efavirenz in Chronically Suppressed HIV-1-Infected Patients with Lipodystrophy (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Does Race Protect an Asian Population from Developing Lipodystrophy in HIV-Infected Individuals on HAART? (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Long-Term Efficacy and Tolerance of Switching the Protease Inhibitor for Non-Nucleoside Reverse Transcriptase Inhibitors: A 52-Week, Multicenter, Prospective Study (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.